Clinical nuclear medicine studies play an important role in the non-invasive evaluation of cardiac physiology and function including myocardial perfusion. The use of nuclear cardiovascular examinations permits the sensitive detection and diagnosis of numerous cardiac abnormalities as well as the determination of the functional consequences and prognosis of coronary artery disease.

Imaging of myocardial perfusion with radiopharmaceuticals is the most commonly performed cardiac examination in clinical nuclear medicine practice. Its primary goal is to determine the adequacy of blood flow to the myocardium, especially in conjunction with exercise or pharmacologic stress for the detection, localization and evaluation of coronary artery disease (CAD).

Product Overview

Product name

kit for radiopharmaceutical preparation


DRAXMIBI is used for:

  • studying the blood circulation, especially the blood circulation in the heart.
  • determining if any areas of the heart muscle have been damaged because of an insufficient blood supply to the heart.
  • the diagnosis of breast cancer when the results of other diagnostic methods are unclear.
  • checking the overactivity of the parathyroid gland, which may be causing an abnormally high activity of this organ.


  • Kit for radiopharmaceutical preparation
  • Lyophilized, white powder
  • To be reconstituted with sodium pertechnetate (99mTc) solution for injection (not included in this kit)


This product is in multi-dose vials presented in a pack of 5 vials in a carton.

Specific Product Characteristics

Click here for SPC

Safety Data Sheet

Click here for MSDS

User Information


This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient. For full Prescribing Information including indications, contraindications, warnings, precautions and adverse events, please see the appropriate product labeling.